Physician profile
Murray R Master
NPI 1366616302
$620.64
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $93.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $118.50 | 2019-2020 | |
| Therapeuticsmd, INC. | $95.69 | 2019-2020 | |
| Allergan, INC. | $70.20 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.86 | 2019 | |
| Millicent US INC | $60.30 | 2019 | |
| Abbvie INC. | $57.95 | 2019-2020 | |
| Lupin INC. | $40.70 | 2019 | |
| Amag Pharmaceuticals, INC. | $35.23 | 2019 | |
| Exeltis, USA INC. | $29.81 | 2019 | |
| Mission Pharmacal Company | $14.26 | 2019 | |
| Coopersurgical, INC. | $14.19 | 2019 | |
| Daiichi Sankyo INC. | $13.95 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Master listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.